Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer
TLS signature 3 predicts CIT response independently of PD-L1, improving outcomes in PD-L1-negative patients and complementing PD-L1 testing. Integration into clinical practice may refine treatment decisions, warranting further mechanistic and clinical validation.
Authors
- Haishuang Sun (ORCID: https://orcid.org/0000-0003-2403-7767)
- Xuan Yang (ORCID: https://orcid.org/0000-0003-1818-2634)
- Shaodong Hong (ORCID: https://orcid.org/0000-0002-5632-6857)
- Yunpeng Yang (ORCID: https://orcid.org/0000-0001-6987-2219)
- Bijing Xiao
- Li Zhang (ORCID: https://orcid.org/0000-0002-7615-4976)
- Dongchen Sun (ORCID: https://orcid.org/0000-0002-7598-3326)
- Wei Du (ORCID: https://orcid.org/0000-0002-7410-9194)
- Wenfeng Fang (ORCID: https://orcid.org/0000-0002-6440-8246)
- Yan Huang (ORCID: https://orcid.org/0000-0002-8182-9376)
- Jianhua Zhan
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1007/s00262-025-04165-2
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- National Science and Technology Major Project
- Guangzhou Municipal Science and Technology Project